Industry News & Updates

Monday ~ February 8, 2010

Two Studies Find Artefill® to Be a Long-Term Treatment Option for Facial Lipoatrophy

Two Studies Find Artefill® to Be a Long-Term Treatment Option for Facial Lipoatrophy

Investigator-Initiated Studies Examine Artefill’s Use with Age-Related and HIV-Associated Facial Lipoatrophy Patients

SAN DIEGO, CA – Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients. The studies were presented at the Advances in Cosmetic and Medical Dermatology’s “Maui Derm 2010” Meeting in Maui, Hawaii January 23-27th and the American Academy of Cosmetic Dermatology (AACS) Scientific Meeting in Orlando, Florida January 28-31st.

A retrospective review of 11 patients was presented by Joseph A. Eviatar, M.D., FACS, Chelsea Eye and Cosmetic Surgery Associates, New York Medical College, at the AACS Scientific Meeting. The study evaluated the safety and efficacy of pan facial soft tissue augmentation with Artefill for the correction of lipoatrophy in HIV patients. Three patients were previously treated with Sculptra, six with Radiesse. Patients received Artefill injections over a six-month period until full correction was achieved. Changes were evaluated from baseline using a 0 to 4 atrophic grading scale. The results showed that all patients had improvement and no adverse events were reported. In total, 54.5 percent of patients improved at least two grades based on this four point grading scale at their evaluation time point, which ranged from 2 to 25 months.

Dr. Eviatar

Dr. Eviatar

Dr. Eviatar commented, “Artefill proved to be effective in restoring volume to the face in these HIV lipoatrophy patients and we believe may offer a more long-term, cost effective treatment option for this patient population.”

In a poster session at Maui Derm 2010, Dr. Farhad Niroomand, Attending, Baylor University Medical Center (Dallas) and Associate Clinical Professor of Dermatology, University of Texas, Southwestern Medical Center, presented a retrospective review of 8 patients, 6 with HIV lipoatrophy and 2 with age-related lipoatrophy, from a pool of 100 Artefill-treated patients. The availability of good pre and post-treatment photographs and the diversity of ethnic backgrounds were the main selection criteria. Patients were treated with Artefill in varied intervals ranging from six weeks to one year and changes were evaluated from baseline. Improvement was seen in all HIV lipoatrophy patients ranging between 50-100 percent. Non-HIV patients experienced overall facial contour improvement.

“We believe Artefill is a viable treatment option for lipoatrophy and non-surgical anti-aging enhancement. Our patients found Artefill to be effective, long-lasting and less painful compared to other fillers,” commented Dr. Niroomand.

About Artefill
Artefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. Since Artefill was approved in 2006, over 20,000 patients have been treated successfully with very high satisfaction rates.

About Suneva Medical
Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company’s lead product is Artefill®, the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines.

Suneva Medical
858.550.9999
www.sunevamedical.com

Source: Suneva Medical

Wednesday ~ February 3, 2010

Allergan, Inc. Announces FDA Approval of JUVÉDERM(R) XC Dermal Filler Formulated with Lidocaine

Allergan, Inc. Announces FDA Approval of JUVÉDERM(R) XC Dermal Filler Formulated with Lidocaine

First and Only Hyaluronic Acid Filler Approved to Last up to One Year from Initial Treatment Now Available with Lidocaine Providing Patients a More Comfortable Injection Experience

IRVINE, Calif. (BUSINESS WIRE) — Allergan, Inc. (NYSE:AGN) today announced the U.S. Food and Drug Administration’s (FDA) approval of JUVÉDERM(R) XC, a new formulation of the currently FDA-approved JUVÉDERM(R) dermal filler and the latest advancement1 in hyaluronic acid (HA) dermal fillers. Allergan’s new JUVÉDERM(R) formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or “parentheses”) that appear around the nose and mouth. JUVÉDERM(R) is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2 and number-one selling hyaluronic acid dermal filler.3

Juvederm

“As the global leader in medical aesthetics, Allergan is committed to providing the latest scientific advancements in facial aesthetic products to meet patients’ demands and further optimize their experiences,” said Robert Grant, Allergan’s Corporate Vice President and President, Allergan Medical. “We lead innovation in the dermal filler category with the first and only smooth-consistency gel hyaluronic acid dermal filler approved by the FDA to last up to a year. Now we have added lidocaine to JUVÉDERM(R) to provide the same smooth, long-lasting result, but with additional comfort for patients.”

The JUVÉDERM(R) XC formulation with 0.3% preservative-free lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic. JUVÉDERM(R) XC provides the same smooth, long-lasting results as demonstrated with existing formulations of JUVÉDERM(R), and now offers a more comfortable injection experience and potentially less time spent in the physician’s office when compared to the non-lidocaine JUVÉDERM(R) formulation.

“Patients want a smooth and natural-looking result from a dermal filler treatment, but as a physician I am also interested in managing my patient’s discomfort during the injection. Before the introduction of JUVÉDERM(R) XC it often took up to 30 minutes for an anesthetic block to take effect. In the clinical trial leading up to the FDA approval, patients reported they experienced less pain with JUVÉDERM(R) XC, compared to their previous dermal filler treatment without lidocaine. So with the new formulation, patients can receive the same smooth results as demonstrated with JUVÉDERM(R) but enjoy a more comfortable injection experience,” said Charles Boyd, M.D., Boyd Cosmetic Surgical Institute and JUVÉDERM(R) XC clinical investigator.

The FDA approval of JUVÉDERM(R) XC was based on data from a multicenter, double-blind, randomized clinical trial. A total of 72 subjects were followed for two weeks after treatment with one of two JUVÉDERM(R) formulations (JUVÉDERM(R) XC with lidocaine or JUVÉDERM(R) without lidocaine) in each nasolabial fold. In the clinical study (n=72), 93 percent of patients reported less pain when treated with the new formulation of JUVÉDERM(R) compared to those treated with the non-lidocaine formulation of JUVÉDERM(R).4 JUVÉDERM(R) XC was found to be more effective in reducing procedural pain during correction of facial wrinkles and folds while maintaining a similar safety and effectiveness profile to the non-lidocaine formulation of JUVÉDERM(R).

Following FDA’s approval, the new formulation of JUVÉDERM(R) with lidocaine is available for ordering nationwide. JUVÉDERM(R) is a prescription-only treatment and should be administered by a qualified medical practitioner who has been trained in JUVÉDERM(R) injection techniques. To locate a trained medical practitioner in your area, please visit www.Juvederm.com.

Allergan encourages individuals interested in being treated with the JUVÉDERM(R) family of products to visit www.Juvederm.com and access the JUVÉDERM(R) Online Treatment Visualizer to upload a picture and help visualize how JUVÉDERM(R) can potentially smooth away moderate to severe facial wrinkles and folds. This tool is for visualization and illustrative purposes only and is not a substitute for a consultation with a qualified medical practitioner.

JUVÉDERM(R) Family of Products
Allergan’s JUVÉDERM(R) dermal filler product line includes JUVÉDERM(R) Ultra and JUVÉDERM(R) Ultra Plus in the United States, providing physicians with the flexibility to tailor each treatment to the particular needs of the patient. Both of these formulations will now be offered with lidocaine under the brand names, JUVÉDERM(R) Ultra XC and JUVÉDERM(R) Ultra Plus XC. JUVÉDERM(R) XC is contraindicated in patients with a history of allergies to lidocaine.

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM(R) Injectable Gel
Indication: In the United States, JUVÉDERM(R) injectable gel (including JUVÉDERM(R) Ultra, JUVÉDERM(R) Ultra Plus, JUVÉDERM(R) Ultra XC, and JUVÉDERM(R) Ultra Plus XC) is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Contraindications
JUVÉDERM(R) injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM(R) should not be used in patients with a history of allergies to Gram-positive bacterial proteins. JUVÉDERM(R) Ultra XC and JUVÉDERM(R) Ultra Plus XC should not be used in patients with a history of allergies to lidocaine.

Warnings
JUVÉDERM(R) injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled.

Precautions
The safety of JUVÉDERM(R) for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM(R) injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM(R) should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body’s immune response, as there may be an increased risk of infection. The safety of JUVÉDERM(R) in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM(R) injectable gel, or if JUVÉDERM(R) is administered before the skin has healed completely after such a procedure, there is a possible risk of an inflammatory reaction at the treatment site.

Adverse events
The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less).

Allergan
877.345.5372
www.juvederm.com

Source: Allergan

Universal Companies’ 2010 Spa Resource Book

Universal Companies’ 2010 Spa Resource Book

Simplifying the Way Spas Do Business

Abingdon, VA – Universal Companies’ 2010 catalog, always the preeminent resource for the spa industry, aims to help simplify shopping for spa owners and operators. One of the most comprehensive resources available to spas, the annual Spa Resource Book is the prime example of how Universal Companies can serve as “Your One Source Spa Solution®.”

Universal Logo

“Now more than ever, our challenge to help the spa industry thrive resonates, and this year’s catalog is filled with ideas and products to help our customers recover from the difficult past months,” said Universal Companies Founder Marti Morenings. “We hope it gives them the same renewed optimism that we feel.”

The 2010 edition of the Spa Resource Book features more than 5,000 spa products, including hundreds of new professional and retail items, as well as many favorite products. It also introduces more than 30 exciting new brands. In an ongoing effort to consistently deliver innovative spa solutions to maximize the success of our partner-customers, many offerings are exclusive to Universal Companies.

Shop the 2010 Spa Resource Book online and find out how Universal Companies can be “Your One Source Spa Solution®” by visiting the Universal website.

To learn more about our educational programs please visit www.AdvanceWithEducation.com.

To receive a free copy of the catalog, call 800.558.5571.

About Universal Companies
Universal Companies is the leading single-source supplier to the spa industry, providing thousands of products to help day spas, resort spas, medical spas, and independent practitioners manage and grow their businesses. An early innovator in the spa industry, Universal has forged strong partnerships with hundreds of manufacturers to create unique and effective products that meet the needs of the business owner or spa practitioner. Universal Companies prides itself in “simplifying” the demands placed on spa operators by being a “one source spa solution” and providing numerous resources, including consultative selling and education.

Universal Companies
800.558.5571
www.universalcompanies.com

Source: Universal Companies

Thursday ~ January 28, 2010

New Mederma® Stretch Marks Therapy

Coming Soon: New Mederma® Stretch Marks Therapy

New Product From The Makers Of The #1 Doctor-Recommended Scar Brand

This February, NEW Mederma® Stretch Marks Therapy will be available at CVS, Walgreens and other retail drug stores across the country.

Mederma® Stretch Marks Therapy is specifically formulated and clinically proven to improve overall appearance of stretch marks, with noticeable improvement in as soon as four weeks.

Mederma

With an advanced, dermatologist-tested cream formula that combines a unique blend of ingredients, including the proprietary botanical extract Cepalin®, hyaluronic acid and centella asiatica leaf extract, Mederma® Stretch Marks Therapy is the newest addition to the Mederma® family of products.

How to Use

· Mederma® Stretch Marks Therapy should be applied evenly and gently massaged into all areas of the body where stretch marks are present two times a day. For best results, apply an amount sufficient to cover the affected area(s) in the morning and evening and massage into your skin in a circular motion until absorbed.

· With consistent use as directed, you should begin to see noticeable improvement in about four weeks and optimum improvement in 12 weeks.

Availability

· Mederma® Stretch Marks Therapy is available in a 5.29-oz tube (a one month supply, on average) and retails for approximately $39.99.

· Mederma® Stretch Marks Therapy will be available in the skin care section of CVS and Walgreens® stores in February 2010, and in other drug stores nationwide beginning in March 2010.

Medical Dynamics - Mederma
888.925.8989
www.mederma.com

Source: Medical Dynamics

Monday ~ January 25, 2010

Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill®

Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill®

Study Suggests Artefill Is As Safe as Other Dermal Fillers for Nasolabial Fold Correction

Data Presented at Maui Derm 2010 Meeting

MAUI, HAWAII — January 25, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.

Maui Derm logo

The data is being presented by study investigator W. Philip Werschler, M.D., FAAD, FAACS, Assistant Clinical Professor in Medicine/Dermatology at University of Washington, at the Advances in Cosmetic and Medical Dermatology’s “Maui Derm 2010” Meeting taking place in Maui, Hawaii January 23-27th.

Dr. Werschler commented, “Our initial analysis is very encouraging as it further validates Artefill’s strong safety profile and high level of patient satisfaction for long-term wrinkle correction. A granuloma incidence rate of less than 0.1% is also indicative of this and suggests Artefill is as safe as other dermal fillers, such as Juvederm and Restylane.”

The 23-center, prospective, open-label study consists of 1,008 patients who had no recent history of nasolabial fold correction. Patients received an initial treatment with Artefill, and up to two touch-ups after 30 and 60 days, until full correction was achieved. Potential adverse events and satisfaction data are reported by all patients at 2, 6, 12, 18, 24, 36, 48 and 60 months to assess the presence of or absence of adverse events, patient satisfaction, and any changes in health. Potential subject-reported AEs were followed up by phone (non-device related) and/or office visit and possible granulomas were analyzed by biopsy. All study patients will complete a final in-office visit at 60-months.

Suneva Logo

Niv Caviar, President and Chief Executive Officer of Suneva Medical commented, “These results are consistent with what we observed during the pivotal trial and further validate Artefill’s role as a long-lasting filler in the aesthetic market. We look forward to reporting additional interim results later this year as more patients reach the two-year point.”

About Artefill
Artefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. Since Artefill was approved in 2006, over 20,000 patients have been treated successfully with very high satisfaction rates. For more information visit www.artefill.com.

About Suneva Medical
Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company’s lead product is Artefill®, the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines.

Suneva Medical
858.550.9999
www.sunevamedical.com

Source: Suneva

Friday ~ January 22, 2010

Healthcare 2010: What’s in Store?

Healthcare 2010: What’s in Store?

Several of e-health’s leading thinkers offer their perspectives on what promises to be a landmark year in the industry.

No one can predict the future—except for Oprah, maybe, but that’s beside the point. Despite our lack of forecasting skills, it’s always fun to use our experience to take an educated look forward to what’s coming down the road.

To ascertain what may lie ahead in the health information field, For The Record (FTR) posed a series of questions to some of the industry’s brightest minds—with one exception. Sal Obfuscato, executive director of SEEDIE (the Society for Exorbitantly Expensive and Difficult to Implement EHRs), clearly is out of his league here, but he gives it his best shot. In all seriousness, although Obfuscato’s answers are tongue-in-cheek, like most satire, they contain elements of truth that others may want to ignore.

The rest of the esteemed lineup features Deborah Kohn, principal of Dak Systems Consulting; Lorraine Fernandes, RHIA, senior vice president and healthcare ambassador for Initiate Systems; Carl Cottrell, vice president of product management at eWebHealth; Claudia Tessier, RHIA, president of the mHealth Initiative; Shelley Myers, RN, MS, CPHIMS, healthcare informatics specialist at User Centric; Jeff Margolis, chairman and CEO of TriZetto; and Glen Moy, a senior program officer at the California HealthCare Foundation.

HIPAA logo

FTR: What topic/issue currently not making headlines will become big news in 2010?

Kohn: HIPAA 5010 and ICD-10.

Tessier: Participatory health enabled by mobile phones and other mobile devices will get increasing attention. Patients, providers, payers, and other healthcare stakeholders are no longer tethered to a PC or landline. Over 5,000 mobile apps are now available, and the number is rapidly increasing. Patients can be reminded of appointments and lab tests via text messaging and e-mails. They can research conditions and treatment through professional resources, as well as patient groups, often turning to the Internet for a second opinion. They can monitor their blood sugar, blood pressure, diet, exercise, and more with mobile apps. Disease management tools enable patients and providers to monitor chronic conditions not just at the time of office visits but routinely, even daily, with observations of daily living. Eligibility and sometimes even copays can be determined via cell phone. Web resources are readily available, allowing patients and providers to quickly identify potential drug interactions. Providers can consult ad hoc with online resources, as well as international colleagues. Public health monitoring can identify disease outbreaks and trends, as well as disasters, and communicate alerts to the public and to healthcare providers. Emergency providers can wirelessly record and forward patient data to the ED [emergency department] so that triage can begin before the patient arrives there. And so much more.

Myers: HIT Extension Program grants, HIT usability—how to measure and improve, CCHIT [Certification Commission for Health Information Technology] incorporating usability evaluation into certification process—more physicians utilizing the CCR [Continuity of Care Record] and CCD [Continuity of Care Document] standards to share information electronically with their patients and other care providers, and patient/consumer empowerment … on the rise and working well.

Fernandes: I believe data sharing (or data exchange) on a local/private/proprietary basis will gain greater visibility and focus. This type of data sharing is defined by the needs of a single healthcare enterprise to compete more effectively for the physicians in their service area or local community. It’s focused on providing a competitive advantage by creating physician affinity with the healthcare enterprise via orders and results sharing (either via EMR or fax machine) or by providing a longitudinal view through a clinical portal. It is likely to be driven by the competitiveness of the market, the volume of private practice physicians in the region, and existing brand loyalty. This data-sharing approach addresses coordinated care priorities like sharing referrals, orders, and lab and imaging results.

There will be minimal conflict around the governance of sharing of information. And the value (return on investment) is probably far more tangible than regional, state, or national data sharing. After all, healthcare is largely local and remains competitive at that level. State initiatives clearly will receive high exposure since ONC [the Office of the National Coordinator for Health Information Technology] is releasing funding in the very near term, but I think the efforts toward serving the local community will accelerate.

Cottrell: The importance of having an electronic legal health record (e-LHR) in addition to a clinical electronic health record because the e-LHR will meet the needs of the expanded HIPAA security rule. Under the expanded HIPAA security rule requirements (that take effect in February), covered entities will be faced with new rules regarding expanded accounting for disclosures, giving patients who pay for their own services the ability to restrict disclosure of their records upon request and providing records to patients electronically upon request. However, covered entities typically lack the IT infrastructure necessary to meet these new requirements. This is because EHRs are designed primarily for clinical use, not for fulfilling external record requests.

The discussions regarding meaningful use have focused almost exclusively on the clinical EHR criteria and related health information exchange, not the administrative requirements which fall in the domain of the legal health record. It is vital that healthcare organizations understand the difference between the clinical EHR and the LHR—the record used to document and support billing, legal, and administrative processes. Insufficient e-LHR capabilities will result in cost implications in the form of potential HIPAA fines and penalties, as well as lost reimbursement opportunities under ARRA [the American Recovery and Reinvestment Act] funding programs when the EHR initiative fails to meet all criteria.

Moy: One issue that has been overlooked is the capacity of ancillary providers (eg, clinical laboratories, pharmacies, etc) to support the increased demand for health information exchange as a result of meaningful use. For example, many hospital and reference laboratories will be inundated with requests from local small physician practices for interfaces in order to send lab orders and receive lab results electronically. However, most laboratories do not have the resources to implement numerous individual interfaces, and many hospital-based laboratory information systems are not designed to push lab results outside the walls of the hospital. As for pharmacies, there is an assumption that the majority of pharmacies are ready to receive and process electronic prescriptions. But at the local level, many pharmacies require retraining and changes to workflow in order to handle e-prescriptions.

Margolis: Once the demonization of health plans—which appears politically necessary for healthcare legislation to pass—subsides, payer-based personal health records will begin to be understood as a complementary method of achieving rapid and cost-effective health information exchange across providers and among consumers and providers. The real cost of implementing and maintaining provider-based EHR solutions and the inherent change-management challenges of implementing software-based solutions will gain more exposure. Both types of records are positive contributions to fixing the state of healthcare.

Obfuscato: Britney Spears has certainly been quiet. We expect to hear more from her in the coming year. Our research also indicates physician depression will hit an all-time high in 2010 as cash-strapped practices use hoped-for stimulus funds to purchase expensive, client-server EHR systems that transform clinicians from productive and cognitive practitioners of the medical arts into lumbering clerks who perform data-entry functions for the few patients they can see in a day. All in all, it looks to be a great year, especially for those who invest in pharma companies with significant SSRI market share.

FTR: Will meaningful use become nothing more than a selling point for EHR vendors?

Kohn: I really don’t know. Most of this topic is still so vague and uncertain.

Tessier: The risk is strong that just that will happen, particularly with the difficulties encountered in developing a uniform, widely understood and accepted definition.

Myers: Although sales for EHR vendors will increase, anything that we can do to get physicians to not only use EHRs but to use them in a way that will make a positive impact on patient outcomes, patient satisfaction with the care experience, and help to improve care coordination and guideline compliance for those with chronic disease. If there is nothing to light a fire under these physicians to get them to move more quickly on leveraging technology to improve care, it will take years and years … essentially until those who are opposed to technology retire.

Fernandes: Simply computerizing healthcare records will not achieve the outlined priorities. EHRs are certainly important. However, there is nothing in place to prevent the creation of multiple EHRs for a single individual, added by the many organizations serving that patient. The same problems that arise from lack of visibility into medical history, like drug allergies, will persist. Duplicate testing will continue. Money will still be wasted.

For America to get the kind of collaborative care we desperately need—where health providers deliver cost-effective, quality care—it will take more than simply creating EHRs. Unless we get EHRs on the road to reform through interoperability and data exchange, EHRs will only become a new road heading toward the bridge to nowhere.

Margolis: Meaningful use is well intended to actually help raise the level of healthcare quality and reduce costs. For the next several years, however, EHR vendors will use the concept of becoming certified solutions under the meaningful use definition to drive revenue and act as intermediaries to deliver ARRA funds to physicians and hospitals as a financing mechanism to help sell their products and services.

Moy: I think we are already seeing this with various vendors guaranteeing achievement of meaningful use. However, meaningful use is not a product feature like e-prescribing or decision support but the result of providers fully and effectively utilizing their EHRs for patient care. What will impact providers’ achievement of meaningful use will be the effectiveness of their implementation efforts and the support they receive along the way.

Obfuscato: Meaningful use is far more than an EHR vendor selling point—it is now the raison d’etre for every EHR vendor with plans to deliver the inflated returns originally promised to their VCs [vendor contracts]. SEEDIE is recommending that its members view meaningful use as a magical monetary infusion pump and the fastest way to funnel ARRA funds into vendor coffers, with physicians serving as mere “stimulus check endorsers.” In fact, we are launching an initiative called “44 is the Floor,” which encourages EHR vendors to charge exactly $44,000 to implement their systems while providing vague assurances that meaningful use criteria can be met, with the tacit understanding that additional funds will be required for support, upgrades, and the actual demonstration of anything resembling meaningful use.

FTR: Will EHR implementation rates increase this year?

Tessier: There will be increasing adoption this coming year, but it may take another year or two before the pace of that adoption actually increases. Conflicting and sometimes discouraging reports on the impact of EMRs, along with increasing concerns regarding costs and adoption difficulties, may well reinforce the “let’s wait and see” attitude, in turn further delaying increased adoption rates.

Myers: 2009? No, they may actually decrease since everyone was and still is in a holding pattern for the final ARRA/meaningful use requirements. Once those are released and we get a few of the regional extension centers (RECs) up and running, we will see a surge in purchases and deployments. 2010 will be busy.

Obfuscato: There is no question that EHR implementation rates will increase exponentially as EHR vendors employ inflammatory rhetoric designed to incite panic among physician practices. SEEDIE has developed a “Wait to Implement at Your Peril” education packet for vendor communication teams, with messages crafted by the same propaganda team that conceived the healthcare reform death panel rumor campaign and the successful direct TV marketing effort for Snuggies. In fact, our projections indicate that there will be more physicians with an EHR at the end of 2010 than Americans who watch TV wearing a blanket with arms.

FTR: What roadblocks must be tackled this year to pave the way for more electronic health information exchange (HIE)?

Fernandes: Duplicate records must be matched, linked, and resolved to create a single, accurate view of the health history of the individual. That “view” needs to be within reach of the treating healthcare professional. That single, accurate view must bridge the continuum of care.

Margolis: I believe that HIE is the most hoped for and least understood concept in popular print. The fundamental roadblocks to achieving an effective health information exchange are the concepts of aggregation and governance. The point here is that other than in integrated delivery systems, providers are not natural aggregators of populations of lives. So while it may seem second nature that one or two dominant market-share providers in a given geography are natural governance coordinators for that region, this becomes more complex as you get into areas with more distributed providers. This would be an appropriate time to mention that over 80% of insured lives are already aggregated by less than 20 health plans. Between health plans and CMS, you have natural aggregation of the population. While states work to figure out the HIE governance structures, leveraging the aggregation that already exists should be carefully considered.

Moy: One obvious obstacle is the lack of policies, procedures, and mechanisms for managing patient privacy preferences and release of patient health information to designated providers (including the ancillary providers mentioned above). A related roadblock is the range of messaging standards themselves, that is, the specifics of how information is sent and shared. While progress has been made, setting up the ability to share information remains time and effort intensive. And the standards do not fully account for unique aspects of small primary care practices. The California HealthCare Foundation has tried to help overcome some of these obstacles by developing ELINCS (EHR-Lab Interoperability and Connectivity Specification), which standardizes the formatting and coding of electronic messages exchanged between clinical laboratories and ambulatory EHR systems. But there is still much to be done before health information exchange is seamless and ubiquitous.

FTR: Will there be a job explosion in the HIT industry? If so, how will it be filled?

Kohn: I don’t know if we’ll see this, per se, in 2010. But there is no question that HIT jobs will be badly needed beginning in 2011 to 2015 for sure. I just received a notice to attend an important meeting for a REC committee even though the RECs still are not defined. The community colleges are full of hopeful HIT students, but that never guarantees quality and volume.

Tessier: I doubt it, at least not for some time. The economy will have to recover first, and education and training will be necessary, potentially creating a lag between job availability and qualified people to fill those jobs.

Myers: Yes, there already is. We will need folks who can implement systems, conduct user research and usability testing, work with physicians on planning for ARRA/meaningful use, integration work for HIEs, etc. I’m not sure how it will be filled. My guess is that folks (technical and strategic) from other industries will be pulled over and will need to learn healthcare. I hope that we do not see a large surge in people leaving the practice setting (hospitals/clinics) to go work for vendors and consultants. We need those people to stay and will need to pull people in from other industries (grow the workforce vs. shifting around).

Margolis: Yes and no. There will be a “job shift” of integration consultants, project managers, software developers, and support professionals from other vertical markets to the HIT sector. This has already been occurring and will accelerate. People have to remember that HIT means much more than EHRs and includes health plans, analytical solutions, and even administrative solutions for physicians and hospitals. Nonetheless, you will see EHR job training programs in technical trade school and colleges crop up in a viral manner to try and fill technical and functional positions. Over time, the implementation of higher automation is at least partially meant to increase work efficiency, which means that manual and technology-light supported jobs will be partially replaced by automation.

Obfuscato: A jobs explosion is inevitable, as slow-moving EHR vendors with antiquated and labor-intensive implementation models scramble to find talent who can provide practice consulting and training services. Recognizing a potential implementation bottleneck, SEEDIE has created a workforce development program designed to retrain unemployed car salesmen in the wake of auto dealer closures prompted by the GM and Chrysler bankruptcies. This unique program combines new healthcare IT skills with tried-and-true automotive selling techniques. By mid-2010, it will be commonplace to hear an implementation professional ask, “What do I have to do to get you to e-prescribe this medication today?” When asking for software customization, physicians should not be surprised when their consultant replies, “We can deliver this beauty in any color, but the manager says the changes you want are going to take two years and a significant amount of your money.”

FTR: Will the economy still be a major concern for healthcare organizations?

Kohn: Yes. It will improve but slowly.

Tessier: The economy will continue to be a major concern, perhaps more so than ever, particularly with healthcare reform being stalled and potentially deformed rather than reformed. Indeed, some predict the next big crash will be in the healthcare industry.

Margolis: Less so than most other sectors. There is going to initially be more money piling into the sector that will provide some level of courage to make investments. As we look several years out, however, the need to produce greater value for each healthcare dollar spent will place enormous pressure on healthcare entities of all types. This will be less a function of the economy and more a function that current value for healthcare is not good.

Obfuscato: At SEEDIE, our lobbying efforts are aimed at passing a comprehensive healthcare reform bill that will increase medical costs. Healthcare is a significant part of our economy, and we believe that reducing medical spending would have disastrous effects. Instead, we hope to inflate healthcare spending until it is 50% or more of our national economy. We envision disposable income being invested in three industry sectors: snack foods, television programming, and medical care. Americans will spend what little discretionary income they have on chips, ice cream, soda, and cable television. This sedentary, high-calorie existence will increase the need for medical treatment—the kind of therapies that will require significant postprocedure rest and recuperation. This virtuous circle will fuel a new economy.

FTR: What steps need to be taken to get consumers more involved in their own care?

Kohn: This was the key issue at the recent Health 2.0 Conference in San Francisco. The good news is that consumers are becoming more involved in their own care (via the Internet, etc). The bad news is that consumers are still slow to adopt PHRs [personal health records] or technologies that increase their involvement in care because of poor marketing, new systems, poor functionality, etc.

Tessier: Make information and resources readily available. Respond to patient needs and preferences for easy, clear communication. Remove the financial barriers that patients encounter in getting their own information and guide them toward resources that help them understand their health and conditions. Involve patients in the documentation process and encourage/facilitate their adoption of PHRs and CCRs. Mobile devices will play a huge role in promoting and supporting consumer involvement or, as noted above, participatory health.

Myers: Health coaches, more “skin in the game” so they value their care and are motivated to comply with guidelines and recommendations, sharing of data—electronically, via paper, via in-person communications with their physicians. There are a lot of tools available to consumers/patients to manage or learn about their health, but some are not all that usable. Many of the patients who would benefit the most (eg, older patients, those with chronic diseases, rural) are oftentimes the ones who have the most difficulty using these systems. More user research should be conducted to find out where the gaps are and if the tools, devices, Web sites are adding value or might pose safety risks if not used properly.

Fernandes: We must deliver value to the consumer through easier access to appointment scheduling, routine access to tests such as lab and x-ray, and medication lists. When we deliver value to the consumer, they will be willing to engage in a proactive, partnership relationship. Otherwise, it’s the age old “why bother?”

Margolis: Value-based benefits will be a key to increased consumer involvement. Value-based benefits are designs that encourage use of proper care and discourage use of inappropriate/preference sensitive care. The incentives are economic, such as reducing copays or deductibles, for actively following a recommended health improvement plan. You will see such benefit designs increase in 2010 and grow rapidly over the next several years. Ideally, there will be a parallel set of incentives for providers who will actively communicate, using information technology, with consumers.

Obfuscato: We at SEEDIE advocate a new initiative called Medical Homelessness, an alternative to the Medical Home movement. Medical Homelessness pays lip service to consumer involvement and will require significant grant funding for poorly defined and executed pilot projects but will not actually engage consumers in any meaningful way. Medical Homelessness is designed to preserve the status quo, making absolutely certain that patients are confused about where to turn for medical help. Our program is designed to counteract the impact of the medical home, which could have a negative domino effect.

Imagine a slightly obese, borderline diabetic who works closely with a health coach or advocate and learns about his or her risks and makes lifestyle changes and then monitors his health using a PHR. Instead of adding to healthcare costs as a percent of our GDP [gross domestic product], this patient could actually lose weight and avoid diabetes and its potentially lucrative comorbidities. Medical Homelessness will disrupt any attempts at care coordination and encourage consumers to simply feign compliance with care directives.

FTR: Are there any new technologies that could make a dent in improving HIE?

Kohn: One must be careful to define HIE. HIE can be local, interorganizational, or it can be regional/national, intraorganizational. The Internet isn’t a new technology, but it’s the best technology out there for HIE on any level.

Tessier: Mobile communications will help here, too, enabling access to, as well as recording and transmission of, patient information by anyone (authorized), anywhere, anytime. Mobile devices and mobile apps can achieve the communication and interoperability capabilities long sought after by patients, providers, and other stakeholders and promised but not yet fulfilled by the EMR industry.

Margolis: Yes, payer-based personal health records. Nearly 100% of claims data is already digitized. This data includes diagnoses, procedures, date of service, place of service, treating physician, and pharmacy history (to name a few data items). This is a very rich set of data that is complementary to HIE efforts. I believe a payer-based approach could provide an HIE framework for about 1/20th of the cost of building it up from a provider perspective.

Obfuscato: As everyone knows, health information exchange is not a technical challenge—it is a political one. Organizations like SEEDIE exist to erect barriers—information fortresses that protect the proprietary interests of our EHR vendor community. To forestall the trampling feet of interoperability in our walled gardens, SEEDIE has developed a new weapon called the inertia saber. In the coming year, we intend to send jack-booted storm troopers to meetings where there are discussions of topics such as “standards harmonization” or “exchanging discrete data elements.” These SEEDIE soldiers of fortune will deploy their inertia sabers, deftly convincing meeting attendees that true interoperability is a quixotic pipe dream that deserves endless discussion but is not worthy of any concrete action.

Source: For the Record

Five Reasons Why Patients Should Give Up Tanning in the New Year

Five Reasons Why Patients Should Give Up Tanning in the New Year

New York, NY – From a groundbreaking new study confirming that exposure to ultraviolet (UV) light is the most common cause of melanoma to the proposed tax on the use of indoor tanning beds, there are a host of compelling reasons to give up tanning in the new year.

Tanning Bed

“Tanning is harmful and unnecessary,” said Perry Robins, MD, President, The Skin Cancer Foundation. “Skin cancer is the most common form of cancer in the US. Tanning avoidance and effective sun protection are the most important prevention measures one can take.”

1. Studies Link UV Exposure to Melanoma
According to a definitive new study by researchers at The Wellcome Trust Sanger Institute, the genetic mutations that lead to melanoma are primarily caused by UV exposure. For the first time, the researchers identified thousands of mutations that occur in melanomas due to radiation, viruses, and other causes. Above all, these mutations are caused by damage to the skin cells’ DNA by ultraviolet (UV) radiation. According to the Institute, “The melanoma genome contains more than 33,000 mutations, many of which bear the imprint of the most common cause of melanoma — exposure to ultraviolet light.”

In addition, The International Agency for Research on Cancer (IARC), a working group of the World Health Organization, published a landmark report this summer based on exhaustive research placing the UV radiation produced by tanning beds among the most dangerous forms of radiation for humans, alongside other forms including radon and plutonium as well as solar UV radiation. The research cited by the IARC included studies showing that first exposure to tanning beds in youth increases melanoma risk by 75 percent.

2. Tanning Beds Increase the Risk of Nonmelanoma Skin Cancers
People who use tanning beds are 2.5 times more likely to develop squamous cell carcinoma and 1.5 times more likely to develop basal cell carcinoma. Basal cell carcinoma (BCC) is the most common form of skin cancer and can be highly disfiguring if not detected and treated at an early stage. Squamous cell carcinoma (SCC) is the second most common form of skin cancer and is more likely to metastasize and lead to death if not caught early. Approximately 2,500 people die every year from SCC. Studies shows that people with a history of nonmelanoma skin cancers, such as squamous cell and basal cell carcinoma, face twice the risk of developing other malignancies, such as lung cancer, colon and breast cancer.

3. UV Exposure Causes Skin Aging
Up to 90 percent of the visible changes commonly attributed to aging are caused by UV exposure. The cellular damage caused by ultraviolet radiation is cumulative and often irreversible. The destructive process of photoaging – premature skin aging due to UV exposure – produces profound structural changes in the skin including fine wrinkles, deep grooves, blotchiness, sagging and a leathery texture. Some of these changes may appear as early as in one’s twenties in people who have spent a great deal of time exposing their skin to UV radiation during childhood and teen years.

4. Tanning is No Longer Fashionable

Celebrities, models and fashion insiders all know tanning is no longer in style. Countless celebrities such as Kristen Stewart, Amy Adams, Rachel Weisz and Nicole Kidman would never alter their inherently natural beauty and risk damaging their skin by tanning. Sarah Brown, Vogue’s Beauty Director, states it best. “A healthy glow does not mean a tan. A healthy glow means your natural skin tone glowing.” Jane Larkworthy, Beauty Director of W, adds, “I can’t remember the last time I saw a tanned model in my magazine or on the runway. Skin that is not tan is gorgeous.”

5. Proposed tax on indoor tanning
The US Senate’s approval of a 10 percent excise tax on the use of indoor tanning beds as part of the new healthcare reform bill (H.R. 3590) is an important step forward in the fight against skin cancer. This proposed tax, similar to the sin tax on cigarettes, will hopefully serve a double purpose, not only raising billions for health care, but giving people one more excellent reason to protect their health by staying away from tanning salons.

Skin Cancer Foundation
212.725.5176
www.skincancer.org

Source: Skin Care Foundation

Wednesday ~ January 20, 2010

Social Campaign Management: At Long Last

Social Campaign Management: At Long Last

By Gary Stein, ClickZ

A marketing person should always ask one key question when beginning to develop a social media strategy: how much chaos can this organization handle?

Web

If you’re working for a pharmaceutical company, a bank, or a company that makes baby food, the answer is generally “not a lot.” Even freewheeling brands that make soft drinks and salty snacks tend to be a pretty conservative and risk-averse lot. Their answer to how much chaos they can handle: “well…a bit.”

But the honor roll of next generation companies tend to be completely comfortable in an environment where anything may happen. Companies that dive into social media and let everyone tweet seem to be unconcerned that something may get said that will be taken the wrong way or used against them in a court of law. The people who work at big brands have every right to be envious of this crowd and long for the freedom they have to get engaged with consumers and have open and transparent conversations about what’s going on.

The fact remains, however, that businesses just can’t operate this way. We may idolize the open-source, community-driven start up, but it’s hard to sell that to a legal department. It’s hard to sell it to the IT department. It’s just simply hard.

Luckily, that’s about to change.

A Bit of Structure Goes a Long Way
The problem many managers have with allowing social media to spread through their organization is that there’s no structure — not to what is being said, who is saying it, or even to the data itself. It’s all just so free flowing that it would be almost surprising for something to not go wrong.

Primarily, this has been the case because people inside of companies tend to go directly to social networks to engage with social networks. That is, if someone in the marketing department wants to use Twitter, they go to Twitter’s site and start typing.

This would be fine if that person was the only one tweeting within the company, but that’s never the case. If one person is tweeting, you can be sure that someone else is as well. And there’s a great chance of those two people saying conflicting things, causing (at the least) confusion among consumers.

But what if those people didn’t go directly to Twitter to use Twitter? What if they went through some centralized tool that was owned and managed by the company they work for? That way, all actions could be managed, coordinated, and tracked.

Laying an interface on top of Twitter provides exactly the sort of management layer that would enable a corporation to control a “comfortable” level of chaos. They could assign the engagement in social media to key individuals. They could take snippets of content (the 140 characters of a tweet for example) and traffic those out in the same way that they do an ad.

This insight into the management that companies need is driving an entirely new category of tool: social CRM (define); and it couldn’t come at a better time. A recent report released by Cisco claims that, while social media is spreading through organizations like wildfire, governance and control isn’t. Faced with the potential to have to stop doing social media out of head-office concerns, we should expect marketing departments by the truckload to begin adopting and installing social CRM systems.

This move will ultimately help support the continued use and growth of social networks by marketers. The network owners — Twitter, Facebook, and so on — will hopefully see the value in these systems and work more closely with their developers. The network owners will need to realize that their future is directly tied to how comfortable companies are with using their system; a tool that provides that comfort will go a long way.

Social is (again) following the same path as search: once there were third-party tools in place that allowed for measurement and management, the purse strings loosened and real growth occurred.

Getting Started
Today, a handful of tools enable some level of the management over social media that corporations and marketers need. HootSuite and CoTweet have become popular, but certainly others are available. Each one allows a group of people to coordinate among themselves to have a consistent, singular voice in social media.

The tool, however, is never more important than the craftsperson. Even if you have a system in place that allows for coordination, rules and practices are still needed to mandate coordination. Internal policies and decisions about the way in which the brand plans to engage and interact with its customers in this space is really where the first set of changes will come from. These new management tools will help make that easier.

Source: ClickZ

Thermage and Fraxel - Most Talked About Aesthetic Device Brands in 2009

Thermage and Fraxel - Most Talked About Aesthetic Device Brands in 2009

Drive your patient demand by partnering with the most talked about aesthetic device brands Thermage and Fraxel!

In 2009, Thermage & Fraxel were the most talked about aesthetic device brands, with more than TRIPLE the consumer media coverage and unique online visitors than all other skin tightening and resurfacing products.

Fraxel

- Over 2 billion impressions in the television and print outlets like The Today Show, E!, New York
Times and Vogue*

- Nearly 1,100 print and online articles*

- 300 broadcast stories*
.
.
.

Fraxel 2

Maximize your profitability with a partner that is committed to your success!

CLICK HERE to learn more about incorporating Thermage or Fraxel into your practice.

*2009 Thermage & Fraxel combined
Soures: Empower media monitoring, Cohn & Wolf PR, VMS and compete.com
.
.
.
Solta Medical logo
Solta Medical
877.782.2286
www.solta.com

Source: Solta

William Evans, M.D. - Lunch Time Plastic Surgery

William Evans, M.D. - Lunch Time Plastic Surgery

Same results with zero recovery time

Patients can say goodbye to invasive surgery, pain and weeks of hiding from the outside world. With the development of new technology, one can now get rid of fat or fix your crooked nose without undergoing surgery. Whatever the situation may be, there is now a quick, easy and zero recovery-time option for almost any area you’d like to spruce up or trim down.

Dr. Evans
Dr. Evans

Dr. Evans, Medical Director at Enfuse Laser Medical Center and Spa, says new technology is making it possible to undergo procedures without weeks of recovery time. “Now we can do anything from facelifts to liposuction in an hour and you can leave without having to endure the pain and repercussions typically associated with these types of procedures,” says Dr. Evans.

Below are several zero-recovery time alternatives to traditionally invasive surgeries:

* Zerona Laser: Over just two weeks, you can lose up to four inches off your waist or other hard to trim areas. The main focus of the Zerona laser is contouring. You can now focus on areas like love handles or the lower abdomen to remove fat that otherwise won’t seem to go away. The laser depletes the fat cells so they remain in a collapsed state. The body gets rid of the fat from these cells through normal metabolism. The procedure requires six treatments over two weeks and takes about 40 minutes each time.

* Liquid facelift: No more cutting and stitching to get younger, smoother skin. The ‘liquid facelift’, as Dr. Evans coins it, consists of a combination of injections and lasers to reduce fine lines, wrinkles and skin irregularities. The procedure uses Botox injections in the forehead and around the eyes, and fillers are used as needed elsewhere to fill the skin and reduce wrinkles, followed by a CO2 laser treatment to remove a thin layer of blemished skin, and concluded with a Smartlipo treatment under the chin that tightens and firms the skin.

* Injectable nose job: The less-invasive and nearly painless alternative to rhinoplasty, this procedure uses injectable filler, Radiesse to restore symmetry as well as change the shape of the nose. To achieve a true “Wow” affect, it is optimally combined with Botox, fillers and facials. Patients can get back to their normal activities immediately after the procedure.

* Photorejuvenation: Photo rejuvenation is the ultimate solution for those looking to eradicate sun damage or early signs of aging without taking time away from work or social events. Using a specially designed light, the treatment damages the layer under the surface of the skin to activate new collagen growth. Dr. Evans also explains that photo rejuvenation can be used to enhance results of treatments such as laser procedures, chemical treatments, facial scrubs and facelifts.

About Enfuse Laser & Medical Spa
Featured in Glamour, Allure and on FOX Chicago, Enfuse Laser & Medical Spa is the source for all skin and cosmetic laser needs. Medical Director Dr. William Evans uses only the latest technology that has demonstrated lasting results. Operating out of locations in Wicker Park and Lincoln Park, Dr. Evans and his team offer services from skin tightening and rejuvenation to hair removal.

William Evans, M.D.
773.904.8310
www.enfusemedicalspa.com

Source: Dr. Evans

|| Next Entries »

Monday
February 8, 2010

News Archives:

Browse Topics:

Search News:


Syndication:

Admin:

the leading physician journal for aesthetics and wellness